| Cat. No. |
Product Name |
Information |
| PC-45382 |
Rafoxanide
|
Rafoxanide is a salicylanilide anthelmintic agent that also shows to be an allosteric inhibitor of SPAK and OSR1. |
| PC-45368 |
Buparvaquone
Antiprotozoal
|
Buparvaquone is a hydroxynaphthoquinone antiprotozoal drug related to parvaquone and atovaquone. |
| PC-45379 |
Mebendazole
|
Mebendazole is a highly effective, broad-spectrum antihelmintic by selectively inhibiting the synthesis of microtubules in parasitic worms, and by destroying extant cytoplasmic microtubes in their intestinal cells.. |
| PC-45158 |
Doramectin
Antibiotic
|
Doramectin is a derivative of ivermectin that approved for the treatment of parasites, is an active compound against S.mansoni in an NMRI mouse infection model. |
| PC-25444 |
Schistosome p97 inhibitor 739
Parasite p97 inhibitor
|
Schistosome p97 inhibitor 739 is a potent, selective and covalent inhibitor of parasite p97 with IC50 of 150 nM and 320 nM for S. mansoni and H. sapiens p97 respectively. |
| PC-25438 |
Clocinizine
Antiparasite
|
Clocinizine is a chlorinated analogue of cinnarizine, shows potent antischistosomal activity against both male and female parasites with EC50 and EC90 of 4.6 uM and 5.9 uM respectively. |
| PC-25297 |
Fexinidazole
T. brucei inhibitor
|
Fexinidazole (HOE 239) is an orally active, potent nitroimidazole antitrypanosomal agent, shows trypanocidal activity against T. brucei subspecies and strains with IC50 of 0.7-3.3 uM, has the potential for human sleeping sickness (HAT) caused by infection with T. brucei. |
| PC-25293 |
LXE408
Kinetoplastid proteasome inhibitor
|
LXE408 is a potent, selective inhibitor of the kinetoplastid proteasome with IC50 of 0.04 uM (L. donovani proteasome), inhibits L. donovani amastigote proliferation within primary mouse macrophages (IC50=0.04 uM). |
| PC-25292 |
DNDI-VL-2098
Visceral leishmaniasis inhibitor
|
DNDI-VL-2098 is an orally effective preclinical drug candidate for visceral leishmaniasis (VL) with IC50 of 0.17 uM for L. infantum. |
| PC-25291 |
DNDI-0690
Visceral leishmaniasis inhibitor
|
DNDI-0690 is a clinical drug candidate for visceral leishmaniasis (VL), demonstrated excellent in vitro activity against three Old World and three New World cutaneous Leishmania strains (EC50<5 uM). |
| PC-25290 |
DNDI-5561
T. cruzi inhibitor
|
DNDI-5561 is a small molecule inhibitor of T. cruzi and L. infantum with IC50 of 38 uM and 0.2 uM. |
| PC-25202 |
BKI-1841
CpCDPK1 inhibitor
|
BKI-1841 is a highly potent, specific Cryptosporidium calcium-dependent protein kinase 1 (CDPK1) inhibitor with IC50 of 3 nM (CpCDPK1, C. parvum CDPK1) and EC50 of 0.7 uM against C. parvum parasites in Nanoluciferase assays. |
